Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: A therapeutic dilemma

Rossana M. Calderon, Luigi X. Cubeddu, Ronald B Goldberg, Eugene R Schiff

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The beneficial role of statins in primary and secondary prevention of coronary heart disease has resulted in their frequent use in clinical practice. However, safety concerns, especially regarding hepatotoxicity, have driven multiple trials, which have demonstrated the low incidence of statin-related hepatic adverse effects. The most commonly reported hepatic adverse effect is the phenomenon known as transaminitis, in which liver enzyme levels are elevated in the absence of proven hepatotoxicity. This class effect is usually asymptomatic, reversible, and dose-related. However, the increasing incidence of chronic liver diseases, including nonalcoholic fatty liver disease and hepatitis C, has created a new challenge when initiating statin treatment in patients with high cardiovascular risk. These diseases result in abnormally high liver biochemistry values, discouraging statin use by clinicians, fostering treatment discontinuation, and leaving a large number of at-risk patients untreated. A PubMed/MEDLINE search of the literature regarding statin safety (January 1, 1994-December 31, 2008) was performed, using the following search terms: statin safety, statin-related hepatotoxicity, and chronic liver disease and statin use, as well as the specific names of different statins and different liver diseases. Relevant clinical trials, review articles, panel discussions, and guideline recommendations were selected. This review supports the use of statin treatment in patients with high cardiovascular risk whose elevated aminotransferase levels have no clinical relevance or are attributable to known stable chronic liver conditions. For each patient, the decision should be based on an individual assessment of risks and benefits.

Original languageEnglish
Pages (from-to)349-356
Number of pages8
JournalMayo Clinic Proceedings
Volume85
Issue number4
DOIs
StatePublished - Jan 1 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Transaminases
Liver
Therapeutics
Liver Diseases
Safety
Chronic Disease
Foster Home Care
Incidence
Primary Prevention
Hepatitis C
Secondary Prevention
PubMed
MEDLINE
Biochemistry
Names
Coronary Disease
Clinical Trials
Guidelines

Keywords

  • ALT = alanine aminotransferase
  • CHD = coronary heart disease
  • HCV = hepatitis C virus
  • HPS = heart protection study
  • LDL = low-density lipoprotein
  • NAFLD = nonalcoholic fatty liver disease
  • PBC = primary biliary cirrhosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels : A therapeutic dilemma. / Calderon, Rossana M.; Cubeddu, Luigi X.; Goldberg, Ronald B; Schiff, Eugene R.

In: Mayo Clinic Proceedings, Vol. 85, No. 4, 01.01.2010, p. 349-356.

Research output: Contribution to journalArticle

@article{f0f3cb347dae4a84b9818ad9d49499a7,
title = "Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: A therapeutic dilemma",
abstract = "The beneficial role of statins in primary and secondary prevention of coronary heart disease has resulted in their frequent use in clinical practice. However, safety concerns, especially regarding hepatotoxicity, have driven multiple trials, which have demonstrated the low incidence of statin-related hepatic adverse effects. The most commonly reported hepatic adverse effect is the phenomenon known as transaminitis, in which liver enzyme levels are elevated in the absence of proven hepatotoxicity. This class effect is usually asymptomatic, reversible, and dose-related. However, the increasing incidence of chronic liver diseases, including nonalcoholic fatty liver disease and hepatitis C, has created a new challenge when initiating statin treatment in patients with high cardiovascular risk. These diseases result in abnormally high liver biochemistry values, discouraging statin use by clinicians, fostering treatment discontinuation, and leaving a large number of at-risk patients untreated. A PubMed/MEDLINE search of the literature regarding statin safety (January 1, 1994-December 31, 2008) was performed, using the following search terms: statin safety, statin-related hepatotoxicity, and chronic liver disease and statin use, as well as the specific names of different statins and different liver diseases. Relevant clinical trials, review articles, panel discussions, and guideline recommendations were selected. This review supports the use of statin treatment in patients with high cardiovascular risk whose elevated aminotransferase levels have no clinical relevance or are attributable to known stable chronic liver conditions. For each patient, the decision should be based on an individual assessment of risks and benefits.",
keywords = "ALT = alanine aminotransferase, CHD = coronary heart disease, HCV = hepatitis C virus, HPS = heart protection study, LDL = low-density lipoprotein, NAFLD = nonalcoholic fatty liver disease, PBC = primary biliary cirrhosis",
author = "Calderon, {Rossana M.} and Cubeddu, {Luigi X.} and Goldberg, {Ronald B} and Schiff, {Eugene R}",
year = "2010",
month = "1",
day = "1",
doi = "10.4065/mcp.2009.0365",
language = "English",
volume = "85",
pages = "349--356",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels

T2 - A therapeutic dilemma

AU - Calderon, Rossana M.

AU - Cubeddu, Luigi X.

AU - Goldberg, Ronald B

AU - Schiff, Eugene R

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The beneficial role of statins in primary and secondary prevention of coronary heart disease has resulted in their frequent use in clinical practice. However, safety concerns, especially regarding hepatotoxicity, have driven multiple trials, which have demonstrated the low incidence of statin-related hepatic adverse effects. The most commonly reported hepatic adverse effect is the phenomenon known as transaminitis, in which liver enzyme levels are elevated in the absence of proven hepatotoxicity. This class effect is usually asymptomatic, reversible, and dose-related. However, the increasing incidence of chronic liver diseases, including nonalcoholic fatty liver disease and hepatitis C, has created a new challenge when initiating statin treatment in patients with high cardiovascular risk. These diseases result in abnormally high liver biochemistry values, discouraging statin use by clinicians, fostering treatment discontinuation, and leaving a large number of at-risk patients untreated. A PubMed/MEDLINE search of the literature regarding statin safety (January 1, 1994-December 31, 2008) was performed, using the following search terms: statin safety, statin-related hepatotoxicity, and chronic liver disease and statin use, as well as the specific names of different statins and different liver diseases. Relevant clinical trials, review articles, panel discussions, and guideline recommendations were selected. This review supports the use of statin treatment in patients with high cardiovascular risk whose elevated aminotransferase levels have no clinical relevance or are attributable to known stable chronic liver conditions. For each patient, the decision should be based on an individual assessment of risks and benefits.

AB - The beneficial role of statins in primary and secondary prevention of coronary heart disease has resulted in their frequent use in clinical practice. However, safety concerns, especially regarding hepatotoxicity, have driven multiple trials, which have demonstrated the low incidence of statin-related hepatic adverse effects. The most commonly reported hepatic adverse effect is the phenomenon known as transaminitis, in which liver enzyme levels are elevated in the absence of proven hepatotoxicity. This class effect is usually asymptomatic, reversible, and dose-related. However, the increasing incidence of chronic liver diseases, including nonalcoholic fatty liver disease and hepatitis C, has created a new challenge when initiating statin treatment in patients with high cardiovascular risk. These diseases result in abnormally high liver biochemistry values, discouraging statin use by clinicians, fostering treatment discontinuation, and leaving a large number of at-risk patients untreated. A PubMed/MEDLINE search of the literature regarding statin safety (January 1, 1994-December 31, 2008) was performed, using the following search terms: statin safety, statin-related hepatotoxicity, and chronic liver disease and statin use, as well as the specific names of different statins and different liver diseases. Relevant clinical trials, review articles, panel discussions, and guideline recommendations were selected. This review supports the use of statin treatment in patients with high cardiovascular risk whose elevated aminotransferase levels have no clinical relevance or are attributable to known stable chronic liver conditions. For each patient, the decision should be based on an individual assessment of risks and benefits.

KW - ALT = alanine aminotransferase

KW - CHD = coronary heart disease

KW - HCV = hepatitis C virus

KW - HPS = heart protection study

KW - LDL = low-density lipoprotein

KW - NAFLD = nonalcoholic fatty liver disease

KW - PBC = primary biliary cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=77950625119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950625119&partnerID=8YFLogxK

U2 - 10.4065/mcp.2009.0365

DO - 10.4065/mcp.2009.0365

M3 - Article

C2 - 20360293

AN - SCOPUS:77950625119

VL - 85

SP - 349

EP - 356

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -